
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
As a result of the broad spectrum and enhanced potency of the carbapenems, this class of agents has long been held in reserve in an attempt to avoid the development of pathogen resistance to this important group of antimicrobials.